Your session is about to expire
← Back to Search
Other
13C-Spirulina Nitrogen Content GEBT Study
N/A
Waitlist Available
Led By Alex Ryder, MD, PhD
Research Sponsored by Cairn Diagnostics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 weeks
Awards & highlights
No Placebo-Only Group
Summary
The purpose of this study is to determine whether there is a difference in the human in vivo response to 13C-Spirulina meals manufactured using 13C-Spirulina containing different levels of protein (as measured by %nitrogen).
Eligible Conditions
- Gastroparesis
- Delayed Gastric Emptying
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 2 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Difference in vivo 13C-Spirulina GEBT response
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Low Nitrogen GEBT test mealExperimental Treatment1 Intervention
GEBT test meal containing low %N content (below 7%)
Find a Location
Who is running the clinical trial?
Cairn DiagnosticsLead Sponsor
4 Previous Clinical Trials
334 Total Patients Enrolled
4 Trials studying Gastroparesis
334 Patients Enrolled for Gastroparesis
Alex Ryder, MD, PhDPrincipal InvestigatorCairn Diagnostics
2 Previous Clinical Trials
57 Total Patients Enrolled
2 Trials studying Gastroparesis
57 Patients Enrolled for Gastroparesis